ArticleRevista latino-americana de enfermagem2026
Navigation program: comparison of diagnosis-treatment times among breast cancer patients.
Article in Revista latino-americana de enfermagem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveto compare diagnostic-treatment time indicators for care provided to women with breast cancer, according to inclusion in a nursing navigation program.
methodretrospective cohort study conducted at a large hospital. Patients with breast cancer, navigated (n=133) or not (n=226), were included. Sociodemographic and clinical variables were analyzed, and the times (in days) from diagnosis to the start of different treatment modalities constituted the dependent variables. Descriptive and inferential analysis was performed at a significance level of 5%.
resultspatients covered by the Unified Health System had significantly shorter median times between diagnosis and any treatment (77.0) and neoadjuvant chemotherapy (77.0) (p-value < 0.001) than those not covered (100.5 and 112.2, respectively). Patients navigated by supplementary health insurance also had shorter access times to both treatment in general (38.0 versus 47.0; p-value <0.001) and neoadjuvant chemotherapy (31.0 versus 50.0; p-value <0.001). Without considering the health insurance plan, no significant differences were found.
conclusionthe navigation program had a positive impact on the accessibility of breast cancer diagnosis and treatment. Investment in this type of care management promoted by nurses is recommended, with greater emphasis on the Unified Health System.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.